AD109
AD109 is a combination of the selective norepinephrine reuptake inhibitor atomoxetine and the antimuscarinic agent aroxybutynin (HY-B0267C). AD109 shows orally active significantly and reduce the apnea–hypopnea index[1].
Product Specifications
UNSPSC
12352005
Target
Adrenergic Receptor; mAChR
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Inflammation/Immunology
Smiles
CCN(CC)CC#CCOC([C@@](C1=CC=CC=C1)(O)C2CCCCC2)=O.CNCC[C@H](C3=CC=CC=C3)OC4=C(C)C=CC=C4
Molecular Formula
C39H52N2O4
Molecular Weight
612.84
References & Citations
[1]Apnimed reports positive topline results from second phase 3 trial of AD109, reinforcing potential of first oral pill for obstructive sleep apnea. News release. July 23, 2025. Accessed July 23, 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15242776 1 Vial
Lentiviral mouse Uhrf1 shRNA (UAS) - Lentiviral mouse Uhrf1 shRNA (UAS, iRFP) plasmid
Sign In for Pricing
View Details 